first trust dsip 4th quarter 17 2025 PSIP and Payment Report as of 27 January 2026 2017 Quarter Coin Value (P,

7), indicating very high acclimation across at least 18C in the current climate

Benefits include: Average weight loss of up to 15 to 25% in clinical studies Improved portion control and satiety Support for balancing blood sugar and metabolic health GLP-1/GIP Dual Agonists These advanced options activate both GLP-1 and GIP (gastric inhibitory polypeptide) receptors for enhanced appetite control, glucose balance, and fat metabolism

This anti-inflammatory peptide stabilizes overactive mast cells and reduces sensitivity reactions, making it the ideal first peptide to introduce before others, such as BPC-157 or growth hormone peptides

No prescription is required because these products are not marketed as drugs